Half-Dose Versus Full-Dose Alteplase for Treatment of Pulmonary Embolism.

ABSTRACT:

Objectives

Recent evidence suggests that half-dose thrombolysis for pulmonary embolism may provide similar efficacy with reduced bleeding risk compared with full-dose therapy, but comparative studies are lacking. We aimed to evaluate the effectiveness and safety of half-dose versus full-dose alteplase for treatment of pulmonary embolism.

Design

A retrospective cohort study comparing outcomes in patients receiving half-dose (50 mg) versus full-dose (100 mg) alteplase for pulmonary embolism. We used propensity score matching and sensitivity analyses to address confounding and hospital-level clustering.

Setting

Data from 420 hospitals obtained from the Premier Healthcare Database between January 2010 and December 2014.

Subjects

Adult critically ill patients with a

SUBMITTER: Kiser TH 

PROVIDER: S-EPMC6375681 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature